bioscrip inc focus provid home
altern site infus therapi via platform
reason report
compani opportun pt
reimburs nois die think investor
updat estim maintain estim
current bio manag team board made
bio analyst investor day came pivot time
million headwind centuri cure act
purchas solut includ refinanc
organ revenu growth bio gener
first quarter posit organ growth sinc
estim would disappoint bio
acceler revenu growth toward higher end
stevendeitsch cooharrietbook ccorichardden
import disclosur analyst certif page report access current disclosur stephen
inc cover compani client may refer
right team strategi place attent turn growth wind home infus
infus provid hh final rule final health safeti standard home infus therapi supplier must
meet final approv oversight process accredit home infus therapi supplier final
bio scapitalstructureisaconsequenceofyearsofdealactivityandsub-optimalfinanc inthepresent
slightli differ home health industri benefit similar trend shift care home
less chang nwc
less chang nwc
thousand except per share
total revenu
sell gener administr expens
depreci amort
incom continu oper
pre-tax incom loss continu oper
net incom loss continu oper
accru dividend prefer stock
deem dividend prefer stock
net incom loss common
sell gener administr expens
compani report stephen inc
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
